Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Lymphoma, T-Cell, Cutaneous 11Mycosis Fungoides 8Sezary Syndrome 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell, Peripheral 4Leukemia-Lymphoma, Adult T-Cell 4Neoplasms 3Recurrence 2Lymphoma, T-Cell 2Carcinoma 2Advanced Solid Tumors 2Stomach Neoplasms 1Solid Tumor 1Mouth Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Leukemia, T-Cell 1Kidney Neoplasms 1Hematologic Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced/Metastatic Solid Tumors 1

Interventions

pembrolizumab 2Bevacizumab 2vanucizumab 1utomilumab 1trifluridine tipiracil drug combination 1selicrelumab 1mogamulizumab 1Trifluridine 1Standard of Care 1N-(6,6-dimethyl-5-((1-methylpiperidin-4-yl)carbonyl)-1,4,5,6-tetrahydropyrrolo(3,4-c)pyrazol-3-yl)-3-methylbutanamide 1Injections 1HMPL-013 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced/Metastatic Solid Tumors × mogamulizumab × Clear all
NCT02444793 2019-02-27

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

Pfizer

Phase 1 Terminated
24 enrolled 34 charts
Other solid neoplasm

Advanced/Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡